Section 19.1 indicates once drug development reaches the stage where the API is produced for use in drug products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API. Q7A EWG did not believe that any of the exemptions would make a product unsafe.